What is it about?
Authors demonstrate that CD32-chimeric receptor T cell identifies CD32 cell surface ligands on breast cancer cells and exert cytotoxic activity in vitro and in vivo, suggesting a potential innovative immunotherapy approach for breast cancer treatment.
Featured Image
Photo by Angiola Harry on Unsplash
Read the Original
This page is a summary of: Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment, Life Science Alliance, October 2022, Life Science Alliance, LLC,
DOI: 10.26508/lsa.202201590.
You can read the full text:
Resources
Contributors
The following have contributed to this page
